Airsonett, a Swedish developer of clinical airflow technology, had a nice boost this week. According to a study published in the latest issue of journal Thorax, Airsonett’s Protexo device has a significant impact on asthma patient’s quality of life when compared to patients using placebo devices.
Protexo is a temperature controlled laminar air-flow device (TLA) which is positioned over the asthma sufferer while they are sleeping. It is designed to create a downward flow of filtered air which envelopes the user’s breathing zone and protects them from allergens and irritants carried in the convection currents which normally flow over us as we sleep, as demonstrated in the video.
According to the press release:
The authors base their findings on 281 non-smokers (either passive or active), aged between 7 and 70, from six European countries. All of them had poorly controlled atopic (allergic) asthma.
Of these, 189 slept with a TLA device (Protexo) just above their bed for a year. The remainder were given a dummy device.
A validated score was used to assess quality of life before and after the 12-month study period, in conjunction with assessments of symptom control, lung capacity, airway inflammation, and biological indicators of a systemic allergic response.
The results showed a significant difference of 14-15% on quality of life scores between those using Protexo and those using the dummy device.
A steeper fall in nitric oxide – an indicator of inflammation – was seen among those using Protexo, and this was particularly noticeable among those with more severe asthma. Those using this device also had significantly smaller increases in another indicator of persistent and more severe inflammation – immunoglobulin E.
Interestingly, Airsonnet has its origins manufacturing equipment for the clean room industry and produces a number of airflow systems for surgical theaters.